News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,565 Results
Type
Article (42344)
Company Profile (294)
Press Release (672927)
Section
Business (210380)
Career Advice (2091)
Deals (36626)
Drug Delivery (106)
Drug Development (83020)
Employer Resources (175)
FDA (16549)
Job Trends (15396)
News (355917)
Policy (33881)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (6)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2590)
Accelerated approval (2)
Adcomms (21)
Allergies (84)
Alliances (51368)
ALS (85)
Alzheimer's disease (1364)
Antibody-drug conjugate (ADC) (115)
Approvals (16550)
Artificial intelligence (242)
Autoimmune disease (15)
Automation (14)
Bankruptcy (371)
Best Places to Work (11771)
BIOSECURE Act (19)
Biosimilars (107)
Biotechnology (188)
Bladder cancer (56)
Brain cancer (26)
Breast cancer (248)
Cancer (2004)
Cardiovascular disease (163)
Career advice (1749)
Career pathing (30)
CAR-T (141)
Cell therapy (398)
Cervical cancer (18)
Clinical research (67223)
Collaboration (781)
Compensation (451)
Complete response letters (25)
COVID-19 (2652)
CRISPR (40)
C-suite (209)
Cystic fibrosis (101)
Data (1930)
Decentralized trials (2)
Denatured (26)
Depression (39)
Diabetes (251)
Diagnostics (6414)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (114)
Drug pricing (107)
Drug shortages (28)
Duchenne muscular dystrophy (85)
Earnings (87841)
Editorial (33)
Employer branding (21)
Employer resources (149)
Events (114465)
Executive appointments (642)
FDA (17665)
Featured Employer (50)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (693)
Gene editing (101)
Generative AI (20)
Gene therapy (289)
GLP-1 (718)
Government (4499)
Grass and pollen (4)
Guidances (48)
Healthcare (18991)
Huntington's disease (23)
IgA nephropathy (22)
Immunology and inflammation (112)
Indications (27)
Infectious disease (2781)
Inflammatory bowel disease (135)
Inflation Reduction Act (8)
Influenza (46)
Intellectual property (85)
Interviews (322)
IPO (16762)
IRA (47)
Job creations (4055)
Job search strategy (1492)
Kidney cancer (9)
Labor market (34)
Layoffs (471)
Leadership (16)
Legal (8368)
Liver cancer (71)
Lung cancer (291)
Lymphoma (131)
Machine learning (2)
Management (59)
Manufacturing (277)
MASH (62)
Medical device (13401)
Medtech (13406)
Mergers & acquisitions (20325)
Metabolic disorders (650)
Multiple sclerosis (68)
NASH (17)
Neurodegenerative disease (80)
Neuropsychiatric disorders (26)
Neuroscience (1844)
NextGen: Class of 2025 (6637)
Non-profit (4525)
Northern California (2407)
Now hiring (37)
Obesity (353)
Opinion (226)
Ovarian cancer (73)
Pain (85)
Pancreatic cancer (77)
Parkinson's disease (131)
Partnered (20)
Patents (207)
Patient recruitment (94)
Peanut (49)
People (59032)
Pharmaceutical (91)
Pharmacy benefit managers (19)
Phase I (20844)
Phase II (29577)
Phase III (22175)
Pipeline (983)
Podcasts (74)
Policy (120)
Postmarket research (2654)
Preclinical (8834)
Press Release (68)
Prostate cancer (93)
Psychedelics (31)
Radiopharmaceuticals (249)
Rare diseases (369)
Real estate (6251)
Recruiting (67)
Regulatory (22981)
Reports (46)
Research institute (2366)
Resumes & cover letters (358)
Rett syndrome (3)
RNA editing (3)
RSV (37)
Schizophrenia (70)
Series A (123)
Series B (78)
Service/supplier (12)
Sickle cell disease (52)
Southern California (2078)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (29)
Startups (3721)
State (2)
Stomach cancer (14)
Supply chain (60)
The Weekly (45)
United States (21137)
Vaccines (674)
Venture capitalists (37)
Webinars (12)
Weight loss (241)
Women's health (33)
Worklife (15)
Date
Today (123)
Last 7 days (603)
Last 30 days (2557)
Last 365 days (34112)
2025 (7880)
2024 (35772)
2023 (40631)
2022 (51798)
2021 (56329)
2020 (54794)
2019 (47400)
2018 (35772)
2017 (33137)
2016 (32663)
2015 (38617)
2014 (32517)
2013 (27632)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (780)
Alabama (49)
Alaska (7)
Arizona (231)
Arkansas (14)
Asia (40578)
Australia (6498)
California (5492)
Canada (1868)
China (480)
Colorado (247)
Connecticut (257)
Delaware (127)
Europe (86506)
Florida (812)
Georgia (190)
Idaho (57)
Illinois (502)
India (24)
Indiana (298)
Iowa (9)
Japan (144)
Kansas (100)
Kentucky (23)
Louisiana (7)
Maine (60)
Maryland (833)
Massachusetts (4164)
Michigan (211)
Minnesota (368)
Mississippi (2)
Missouri (75)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (62)
New Jersey (1573)
New Mexico (29)
New York (1572)
North Carolina (932)
North Dakota (7)
Northern California (2407)
Ohio (190)
Oklahoma (14)
Oregon (38)
Pennsylvania (1251)
Puerto Rico (9)
Rhode Island (26)
South America (1160)
South Carolina (18)
South Dakota (1)
Southern California (2078)
Tennessee (92)
Texas (823)
Utah (165)
Virginia (135)
Washington D.C. (57)
Washington State (516)
West Virginia (3)
Wisconsin (51)
715,565 Results for "napo pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is a Bronze Sponsor of the 10th Annual Elite Ped-GI Congress, which takes place May 2-4, 2024 in Abu Dhabi in the United Arab Emirates (UAE).
April 29, 2024
·
6 min read
Biotech Bay
Napo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and Survivors
In an effort to shed light on the diverse and profound challenges faced by individuals living with a diagnosis or a history of cancer, Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced they were proud to provide fiscal support for More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer.
September 26, 2023
·
4 min read
Biotech Bay
Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company’s FDA-Approved Prescription Drug
Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that it will exhibit at the Annual Association of Nurses in AIDS Care (ANAC) Conference.
October 18, 2023
·
5 min read
Biotech Bay
MASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family Company
Napo Pharmaceuticals, a Jaguar Health, Inc. family company, announced that a Multinational Association of Supportive Care in Cancer webinar titled “GI Toxicities from Cancer Therapies - Prevention and Management,” taking place Monday, January 29, 2024 from 11:30 AM to 12:30 PM Eastern Standard Time, was made possible by an unrestricted educational grant from Napo.
December 7, 2023
·
4 min read
Biotech Bay
Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
Napo Pharmaceuticals Inc. (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) company, today announced the activation by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for a new crofelemer powder for oral solution formulation for the treatment of microvillus inclusion disease (MVID), an ultra-rare congenital diarrheal disorder (CDD).
August 8, 2023
·
4 min read
Biotech Bay
Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
Napo Pharmaceuticals, Inc. (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the results of a Napo-sponsored survey of 15 US neurologists who treat patients with amyotrophic lateral sclerosis (ALS), and the results of a corresponding Napo-sponsored survey of 15 US individuals who are either ALS patients or caregivers of an ALS patient.
August 16, 2023
·
6 min read
Biotech Bay
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
Napo Pharmaceuticals today announced that the abstract for More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer.
December 6, 2023
·
6 min read
Biotech Bay
Napo Pharmaceuticals, a Jaguar Health Company, Submits Investigational New Drug (IND) Application to FDA for Microvillus Inclusion Disease
Napo Pharmaceuticals Inc., a Jaguar Health, Inc. (NASDAQ:JAGX) company, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a new crofelemer powder for oral solution formulation for the treatment of microvillus inclusion disease (MVID).
June 28, 2023
·
4 min read
Drug Development
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Napo Pharmaceuticals (Napo), a Jaguar Health (NASDAQ:JAGX) (Jaguar) family company, today announced that it has submitted a grant application to the National Institute of Allergy and Infectious Diseases (NIAID) for funding to support Napo’s Phase I study of NP-300.
September 12, 2023
·
5 min read
Drug Development
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) today announced that Jaguar family companies Napo Pharmaceuticals (“Napo”) and Napo Therapeutics have submitted a Clinical Trial Application (CTA) to the Italian and German health authorities to initiate a phase 2 clinical trial of Jaguar’s novel plant-based prescription drug crofelemer for treatment of short bowel syndrome (SBS) with intestinal failure in adults.
May 9, 2024
·
5 min read
1 of 71,557
Next
